United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The “United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)” report has been added to ResearchAndMarkets.com’s offering.
The report analyses the development of the respective market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report.
The US Overactive Bladder market is set to experience favorable growth driven by factors such rising ageing population, increasing health care expenditure, growing obese population, surging diabetic prevalence and increasing coffee intake.
The major trends observed in this market include advancing innovative therapies, increasing awareness for OAB and development of gene therapy.
However, the growth of the market is constrained by challenges such as entry of generic drugs in the market, stringent regulations and side effects of oral therapies of OAB.
The four major players: Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer and Allergan are being profiled along with their key financials and strategies for growth.
Key Topics Covered
1. Market Overview
1.1 Overactive Bladder
1.2 Symptoms & Diagnosis
1.4 Overactive Bladder with BPH
2. US Market Analysis
2.1 Overactive Bladder Market
2.1.1 US Overactive Bladder Market Forecast by Value
2.1.2 US Overactive Bladder Market by Drug Class
2.1.3 US Anticholinergics Market Forecast by Value
2.1.4 US Beta 3 Adrenoreceptor Agonists Market Forecast by Value
2.1.5 US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug
2.1.6 US Vibegron Drug Revenue Forecast
2.1.7 US Vibegron Prescriptions Volume Forecast
2.1.8 US Mirabegron Prescriptions Volume Forecast
2.1.9 US Overactive Bladder Patient Population Forecast
2.1.10 US Overactive Bladder Treated Patient Population Forecast
2.1.11 US Overactive Bladder Prescriptions Volume Forecast
2.2 Overactive Bladder Market with BPH
2.2.1 US Overactive Bladder with BPH Patient Population Forecast
2.2.2 US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate
2.2.3 US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug
2.2.4 US Vibegron Drug Revenue Forecast
2.2.5 US Vibegron Prescriptions Volume Forecast
2.2.6 US Mirabegron Prescriptions Volume Forecast
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Rising Ageing Population
3.1.2 Increasing Health Care Expenditure
3.1.3 Growing Obese Population
3.1.4 Surging Diabetic Prevalence
3.1.5 Increasing Coffee Intake
3.2 Key Trends & Development
3.2.1 Advancing Innovative Therapies
3.2.2 Rising Awareness for OAB
3.2.3 Development of Gene Therapy
3.3.1 Entry of Generic Drugs
3.3.2 Stringent Regulations
3.3.3 Side Effects of Oral Therapies
4.1 Global Market
4.1.1 Revenue Comparison by Company
4.1.2 Market Cap Comparison by Company
5. Company Profiles
Business Overview, Financial Overview and Business Strategies
5.1 Astellas Pharma Inc.
5.2 Hisamitsu Pharmaceutical Co. Inc.
5.3 Pfizer Inc.
5.4 Allergan PLC
For more information about this report visit https://www.researchandmarkets.com/research/b8tmlv/united_states?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005513/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs ,Urological Disorders Drugs,Urology and Nephrology
KEYWORD: UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/21/2018 02:00 PM/DISC: 12/21/2018 02:01 PM